Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
547 stopped studies mapped to Malignant Nervous System Neoplasm and descendants · 90% state a reason
Over the 547 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02924038 | A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II… | Phase 1 | terminated | Oct 5, 2016 | Nicholas Butowski | Industry sponsor decision | Sponsor / business decision |
| NCT04915404 | Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV) | Phase 1 / Phase 2 | terminated | Jun 7, 2021 | WPD Pharmaceuticals Sp. z o.o. | Business decision | Sponsor / business decision |
| NCT01622764 | 89Zr-RO5323441 PET Imaging in Glioblastoma | Phase 2 | withdrawn | Jun 19, 2012 | University Medical Center Groningen | No funding from the sponsor | Funding |
| NCT02624388 | Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)(UVA-Gen001) | Phase 2 | terminated | Dec 8, 2015 | University of Virginia | Poor enrollment | Enrollment / accrual |
| NCT05074992 | A Trial of Neoadjuvant Therapy in Patients With Newly Diagnosed Glioblastoma(NeAT Glio) | Phase 2 | terminated | Oct 12, 2021 | University College, London | Support withdrawn from drug company supplying IMP | Sponsor / business decision |
| NCT04681677 | Recurrent GBM Treated With Neurosurgical Resection and IORT Using the Xoft Axxent eBx…(IORT) | Phase 2 | terminated | Dec 23, 2020 | Xoft, Inc. | unspecified business decision | Sponsor / business decision |
| NCT02085304 | Tumor Resection and Gliadel® Wafers, Followed by Temodar® With Standard Radiation or… | Phase 1 / Phase 2 | terminated | Mar 12, 2014 | St. Joseph's Hospital and Medical Center, Phoenix | met stopping rules for futility | Efficacy / futility |
| NCT02880410 | Feasibility Study on LITT for Newly Diagnosed Glioblastoma(FLAG) | Phase 1 | terminated | Aug 26, 2016 | Monteris Medical | Terminated (failure to enroll) | Enrollment / accrual |
| NCT03927222 | Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade…(I-ATTAC) | Phase 2 | terminated | Apr 25, 2019 | Mustafa Khasraw, MBChB, MD, FRCP, FRACP | Resource shortage | Other (stated, no rule matched) |
| NCT05304663 | Safety and Efficacy of Different Administration Sequences of L19TNF With Lomustine in…(GLIOASTRA) | Phase 1 | withdrawn | Mar 31, 2022 | Philogen S.p.A. | The Sponsor had no further plan for the study in object | Other (stated, no rule matched) |
| NCT02133183 | Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma | Phase 1 | terminated | May 7, 2014 | National Cancer Institute (NCI) | Other - Lapse in funding | Funding |
| NCT02546102 | Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma | Phase 3 | suspended | Sep 10, 2015 | Precision Life Sciences Group | Company is discussing with FDA to reinitiate the trial now. | Sponsor / business decision |
| NCT05952687 | Trial of Idasanutlin and Selinexor Therapy for Children With Progressive/Relapsed AT/RT… | Phase 1 | withdrawn | Jul 19, 2023 | St. Jude Children's Research Hospital | Drug withdrawn by company. | Sponsor / business decision |
| NCT05666349 | Reirradiation and Niraparib in Patients With Recurrent Glioblastoma(RiNG) | Phase 1 | withdrawn | Dec 27, 2022 | University College, London | Funder support withdrawn 13-Oct-2023. Study did not open to recruitment. | Enrollment / accrual |
| NCT03705351 | Tumor Treating Fields With Chemoradiation in Newly Diagnosed GBM | Phase 1 | terminated | Oct 15, 2018 | Providence Health & Services | Prinicipal Investigator departure from institution | Investigator |
| NCT03403361 | Dual-Energy CT on Plan Quality, Dose-delivery Accuracy, and Simulated Outcomes of… | N/A | terminated | Jan 18, 2018 | Washington University School of Medicine | Low accrual | Enrollment / accrual |
| NCT02905643 | Discerning Pseudoprogression vs True Tumor Growth in GBMs | — | terminated | Sep 19, 2016 | Ascension Health | Investigator left institution | Investigator |
| NCT04341311 | Phase I Study of Marizomib + Panobinostat for Children With DIPG(DIPG) | Phase 1 | terminated | Apr 10, 2020 | Dana-Farber Cancer Institute | Withdrawal of support from BMS | Other (stated, no rule matched) |
| NCT03275402 | 131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous… | Phase 2 / Phase 3 | terminated | Sep 7, 2017 | Y-mAbs Therapeutics | Corporate business decision. Not due to safety or efficacy concerns. | Safety / toxicity |
| NCT02768337 | Cambridge Brain Mets Trial 1(CamBMT1) | Phase 1 / Phase 2 | terminated | May 11, 2016 | Cambridge University Hospitals NHS Foundation Trust | Slow recruitment | Enrollment / accrual |
| NCT00089245 | Radiolabeled MAB Therapy in Patients With Refractory, Recurrent, or Advanced CNS or… | Phase 1 | terminated | Aug 5, 2004 | Y-mAbs Therapeutics | Corporate business decision. No safety or efficacy concerns. | Safety / toxicity |
| NCT03458728 | Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients | Phase 1 / Phase 2 | terminated | Mar 8, 2018 | Bayer | no anticipated benefit over available standard therapies | Other (stated, no rule matched) |
| NCT02168270 | Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma | Phase 1 | terminated | Jun 20, 2014 | University of Nebraska | not stated | Not stated |
| NCT04629209 | A Phase II, Open Label Study of ONC201 in Adults With EGFR-low Glioblastoma | Phase 2 | withdrawn | Nov 16, 2020 | Masonic Cancer Center, University of Minnesota | Change in approach to study. | Other (stated, no rule matched) |
| NCT02432417 | The Addition of Chloroquine to Chemoradiation for Glioblastoma, | Phase 2 | withdrawn | May 4, 2015 | Maastricht Radiation Oncology | The study was withdrawn due to a lack of funding. The researchers were unable to secure the… | Funding |
| NCT02530502 | Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly… | Phase 1 | terminated | Aug 21, 2015 | Northwestern University | The protocol was amendment to be stopped after phase I (phase 2 removed from protocol) | Other (stated, no rule matched) |
| NCT04763031 | Recurrent GBM With Maximal Neurosurgical Removal and Treatment With IORT | N/A | terminated | Feb 21, 2021 | Parkridge Medical Center | No potential patients enrolled since first enrollment on 06/27/2022. | Enrollment / accrual |
| NCT03939858 | Bioenergetic Profiling and Cognition in GBM Patients | — | terminated | May 7, 2019 | Wake Forest University Health Sciences | Funding and laboratory access issues, study is closed | Funding |
| NCT02833701 | Bevacizumab and Ascorbic Acid in Patients Treating With Recurrent High Grade Glioma | Phase 1 | terminated | Jul 14, 2016 | University of Nebraska | not stated | Not stated |
| NCT03190967 | T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of… | Phase 1 / Phase 2 | terminated | Jun 19, 2017 | National Cancer Institute (NCI) | The phase II portion was never started as we could no longer get the drug from the manufacturer. | Drug supply |
| NCT02659800 | Study of the Effect NT-I7 on CD4 Counts in Patients With High Grade Gliomas | Phase 1 | terminated | Jan 20, 2016 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Terminated \[NCI decided to terminate ABTC Consortium due to NCI moving in different direction for… | Other (stated, no rule matched) |
| NCT03593993 | A Biospecimen Collection Study in BRAF-V600E Mutated Recurrent Gliomas | — | terminated | Jul 20, 2018 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | low accrual and lack of funds | Enrollment / accrual |
| NCT03971734 | Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the… | Phase 1 | terminated | Jun 3, 2019 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Terminated \[NCI decided to terminate ABTC Consortium due to NCI moving in different direction for… | Other (stated, no rule matched) |
| NCT04167618 | 177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma | Phase 1 / Phase 2 | terminated | Nov 19, 2019 | Y-mAbs Therapeutics | Business priorities | Sponsor / business decision |
| NCT03406273 | Standardized Protocol of Surgery and Radiation for Patients With Brain Metastases in… | N/A | withdrawn | Jan 23, 2018 | Giselle Sholler | No enrollment to study, study closed | Enrollment / accrual |
| NCT03860207 | Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in… | Phase 1 / Phase 2 | terminated | Mar 1, 2019 | Y-mAbs Therapeutics | study terminated due to business priorities | Sponsor / business decision |
| NCT05054400 | Study of Laser Interstitial Thermal Therapy (LITT) Treatment Response Assessment With… | Early Phase 1 | withdrawn | Sep 23, 2021 | M.D. Anderson Cancer Center | 0 participant accrual | Enrollment / accrual |
| NCT02536183 | A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric… | Phase 1 | terminated | Aug 31, 2015 | AeRang Kim | low accrual | Enrollment / accrual |
| NCT04427228 | Single vs Multi-fraction SRS Patients on Immunotherapy(MIGRAINE) | Phase 2 | withdrawn | Jun 11, 2020 | University of Chicago | unable to enroll | Enrollment / accrual |
| NCT04608812 | Convection-enhanced Delivery of OS2966 for Patients With High-grade Glioma Undergoing a… | Phase 1 | terminated | Oct 29, 2020 | OncoSynergy, Inc. | Slow enrollment and financial constraints. | Enrollment / accrual |
| NCT00788125 | Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With… | Phase 1 / Phase 2 | terminated | Nov 10, 2008 | City of Hope Medical Center | Terminated early due a shift in resources after lackluster performance of the drug. | Other (stated, no rule matched) |
| NCT04541225 | Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid… | Phase 1 | terminated | Sep 9, 2020 | Nuvation Bio Inc. | Sponsor decision | Sponsor / business decision |
| NCT05063357 | 131I-omburtamab Delivered by Convection-Enhanced Delivery in Patients With Diffuse… | Phase 1 | withdrawn | Oct 1, 2021 | Y-mAbs Therapeutics | Corporate business decision. Not due to safety or efficacy concerns. | Safety / toxicity |
| NCT04650204 | Perampanel for the Reduction of Seizure Frequency in Patients With High-grade Glioma and… | Phase 4 | terminated | Dec 2, 2020 | Mayo Clinic | The funding sponsor, EISAI, sold the US rights to the medication and can no longer provide it to… | Funding |
| NCT05242146 | GB5121 in Adult Patients With Relapsed/Refractory CNS Lymphoma(STAR CNS) | Phase 1 | terminated | Feb 16, 2022 | GB005, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | Sponsor decision | Sponsor / business decision |
| NCT03332355 | Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies -… | Phase 1 | terminated | Nov 6, 2017 | Vanquish Oncology, Inc. | Business Reasons | Sponsor / business decision |
| NCT01721577 | Phase I/II Trial of AXL1717 in the Treatment of Recurrent Malignant Astrocytomas(AXL1717) | Phase 1 / Phase 2 | terminated | Nov 5, 2012 | Rush University Medical Center | Investigator went to another institution. | Investigator |
| NCT04741984 | Monocyte Antigen Carrier Cells for Newly Diagnosed GBM(DEMAND) | Phase 1 | withdrawn | Feb 5, 2021 | Michael Gunn | Due to need to proceed with procedural changes with goals of improving the technical and economic… | Other (stated, no rule matched) |
| NCT03055208 | Early Stereotactic Gamma Knife Radiosurgery to Residual Tumor After Surgery of Newly…(Gamma-GBM) | N/A | suspended | Feb 16, 2017 | Universitätsmedizin Mannheim | suspended due to low accrual rates | Enrollment / accrual |
| NCT05590273 | Forgotten Voices: Addressing Unmet Needs in Brain Tumor Caregivers(AIM 2) | N/A | terminated | Oct 21, 2022 | Virginia Commonwealth University | Insufficient caregiver participation | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jun 14, 2024source: clinicaltrials